Samson Rock Capital LLP purchased a new stake in shares of Solventum Corporation (NYSE:SOLV - Free Report) during the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm purchased 33,000 shares of the company's stock, valued at approximately $2,509,000. Solventum accounts for about 4.7% of Samson Rock Capital LLP's portfolio, making the stock its 2nd biggest position.
A number of other institutional investors and hedge funds have also bought and sold shares of the business. Perigon Wealth Management LLC grew its position in shares of Solventum by 3.8% during the first quarter. Perigon Wealth Management LLC now owns 4,352 shares of the company's stock valued at $331,000 after purchasing an additional 159 shares in the last quarter. MassMutual Private Wealth & Trust FSB grew its position in shares of Solventum by 22.3% during the first quarter. MassMutual Private Wealth & Trust FSB now owns 937 shares of the company's stock valued at $71,000 after purchasing an additional 171 shares in the last quarter. EP Wealth Advisors LLC grew its position in shares of Solventum by 3.6% during the fourth quarter. EP Wealth Advisors LLC now owns 5,272 shares of the company's stock valued at $348,000 after purchasing an additional 181 shares in the last quarter. Brown Lisle Cummings Inc. grew its position in shares of Solventum by 22.0% during the first quarter. Brown Lisle Cummings Inc. now owns 1,038 shares of the company's stock valued at $79,000 after purchasing an additional 187 shares in the last quarter. Finally, Avantax Advisory Services Inc. grew its position in shares of Solventum by 2.2% during the fourth quarter. Avantax Advisory Services Inc. now owns 8,835 shares of the company's stock valued at $584,000 after purchasing an additional 192 shares in the last quarter.
Solventum Trading Down 2.8%
NYSE SOLV traded down $2.13 during trading on Friday, hitting $73.75. The stock had a trading volume of 715,871 shares, compared to its average volume of 1,110,569. The company has a debt-to-equity ratio of 2.40, a quick ratio of 0.85 and a current ratio of 1.19. The stock has a market capitalization of $12.76 billion, a price-to-earnings ratio of 34.14, a P/E/G ratio of 1.89 and a beta of 0.55. Solventum Corporation has a one year low of $47.16 and a one year high of $85.92. The stock has a 50 day simple moving average of $73.53 and a 200 day simple moving average of $72.46.
Solventum (NYSE:SOLV - Get Free Report) last announced its quarterly earnings data on Thursday, May 8th. The company reported $1.34 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.19 by $0.15. The business had revenue of $2.07 billion during the quarter, compared to the consensus estimate of $2.02 billion. Solventum had a net margin of 4.55% and a return on equity of 31.01%. The firm's quarterly revenue was up 2.7% compared to the same quarter last year. During the same quarter last year, the firm earned $2.08 earnings per share. Sell-side analysts predict that Solventum Corporation will post 6.58 earnings per share for the current year.
Analyst Ratings Changes
Several research analysts recently commented on SOLV shares. Argus upgraded Solventum from a "hold" rating to a "buy" rating and set a $90.00 price target for the company in a research report on Tuesday, July 1st. KeyCorp started coverage on Solventum in a research report on Friday, June 6th. They issued a "sector weight" rating for the company. Finally, Piper Sandler upgraded Solventum from a "neutral" rating to an "overweight" rating and lifted their price target for the stock from $78.00 to $87.00 in a research report on Monday, May 19th. One analyst has rated the stock with a sell rating, seven have issued a hold rating and three have issued a buy rating to the stock. According to MarketBeat, the stock has an average rating of "Hold" and an average price target of $81.50.
Read Our Latest Stock Report on Solventum
Solventum Profile
(
Free Report)
Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.
Further Reading
Before you consider Solventum, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Solventum wasn't on the list.
While Solventum currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
